ISBT 2011 Lisbon  
 

Symposium

Pathogen Inactivation in Practice: INTERCEPT Platelets and Plasma for Support of Routine and Special Care Patients 

Platelets and plasma treated with the INTERCEPT Blood System are approved for all indications of conventional platelets and plasma, and hundreds of thousands of units have been transfused throughout Europe. This symposium examined important parameters of clinical performance, results from a recent INTERCEPT observational cohort study in Switzerland, and the experience of EFS Alsace in supporting a region of 2 million inhabitants exclusively using INTERCEPT-treated platelets and plasma for several years. Particular attention was focused on the French experience with liver transplant patients, a population with profound haemostatic instability requiring extensive transfusion support with both platelets and plasma.

Speakers:

• CHAIR: Dr Matilde Santos, Head Blood Component Production - IPS Lisbon, Portugal
• Dr. Miguel Lozano, Head of Hemotherapy - Hospital Clinic Barcelona, Spain
• Dr. Andreas Buser, Director – BSD SRK Basel, Switzerland
• Dr. Daniel Kientz, Section Head of Blood Products Delivery – University of Strasbourg, France

Oral Presentation

4A-S15-03: Pathogen Inactivation Validation and Implementation of the INTERCEPT Blood System for Platelets for Pathogen Inactivation of Apheresis and Buffy-Coat Products at One of the Biggest Regional Blood-Centers of Switzerland
D Goslings, P Lodemann, G Yavuzcan et al.
[Abstract PDF]
 

Poster Presentations

Download the INTERCEPT Abstract Compilation from the Congress

INTERCEPT Blood System for Platelets

[P-193] First Validation and Implementation of the Orbisac System in a Swiss Bloodcenter within the Scope of Introducing the Pathogen Inactivation System INTERCEPT
D Goslings, A Valek and BM Frey.
[Abstract PDF]

[P-264] Cumulative Clinical Data of INTERCEPT Blood System™ for Platelets Demonstrate Ability to Replace Gamma Irradiation in Routine Clinical Use for TA-GVHD Prevention
L Lin, A Stassinopoulos, L Corash.
[Poster PDF]

[P-271] Hemostatic Efficacy of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation and Stored for 5 and 7 Days Prior to Transfusion
Laurence Corash, Claire Sherman, William Reed et al.
[Poster PDF]

[P-272] Validation of Double Dose Pooled Platelet Products for Pathogen Inactivation with the INTERCEPT Blood System and Storage for up to 7 Days
Mohammad R Abedi, AC Doverud.

[P-252] Pathogen Reduction Treatment Using Amotosalen and Ultraviolet-A Light: Process Control
A Castrillo Fernández, C Arcas Otero, MI Rodriguez Calvo.

P-269] Two Years Of Experience With The Transfusion Of Pathogen Inactivated Platelets Using The INTERCEPT Blood System™ And 7 day Storage
D Domanovic, M Cukjati, A Milojkovic.

INTERCEPT Blood System for Plasma

[P-174] Analysis of Functional Activity of a Large Panel of Coagulation Factors in Fresh and Previously Frozen Plasma Treated with the INTERCEPT Blood System
M Yáñez Izquierdo, E Fernandez Fontecha, MA Moya San Pedro et al.
[Abstract PDF]

[P-254] The Influence of Different Holding Conditions of Coagulation Parameters of Plasma After Pathogen Reduction with the INTERCEPT Treatment
B Baumann-Baretti, G Jaster, B Brys et al.

[P-268] Photochemical Treatment of Fresh Plasma. Evaluation of Functional Activity of Coagulation Factors and Inhibitors
Francisco Dias, Marika Bini-Antunes, Mónica Pereira et al.
[Abstract PDF]
 

INTERCEPT Blood System for Red Blood Cells

[P-262] In Vitro Evaluation of Pathogen Inactivated RBC Using the S-303 Treatment System
Anna Erickson, Reinhard Henschler, Karin Janetzko et al.
[Poster PDF] [Abstract PDF]
 

Cerus Booth

We’d like to thank everyone who stopped by the Cerus booth, attended the INTERCEPT symposium, and participated in the champagne celebration.

(click thumbnails to enlarge)